On 28 June 2019, orphan designation EU/3/19/2176 was granted by the European Commission to Swedish Orphan Biovitrum AB (publ), Sweden, for recombinant human coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein (also known as BIVV001) for the treatment of haemophilia A.
Recombinant human coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein
|Disease / condition||
Treatment of haemophilia A
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: